LBA
AQST icon

Letko, Brosseau & Associates’s Aquestive Therapeutics AQST Stock Holding History

Letko, Brosseau & Associates’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$147K Hold
35,325
– – ﹤0.01% 95
2025
Q4 		$228K Buy
+35,325
New +$220K ﹤0.01% 90

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Letko, Brosseau & Associates's AQST Position: Q1 2026 in Review

Letko, Brosseau & Associates held its Aquestive Therapeutics (AQST) position steady in Q1 2026 at 35,325 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #95.

Letko, Brosseau & Associates first reported a position in AQST in Q4 2025 and has held it in 2 quarters since. The position peaked at $228K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Letko, Brosseau & Associates held 35,325 shares of Aquestive Therapeutics worth $147K as of Q1 2026.
  • Letko, Brosseau & Associates left its Aquestive Therapeutics share count unchanged in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #95 holding.
  • Letko, Brosseau & Associates first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Letko, Brosseau & Associates's Aquestive Therapeutics position peaked at $228K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.